/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Gossamer Bio Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$3.37 0.1438(14.38%) GOSS at 04 Dec 2025 04:33 PM Biotechnology
Lowest Today 3.01
Highest Today 3.45
Today’s Open 3.015
Prev. Close 2.99
52 Week High 3.60
52 Week Low 0.67
Day’s Range: Low 3.01 High 3.45
52-Week Range: Low 0.67 High 3.60
1 day return -
1 Week return +2.55
1 month return +48.8
3 month return +35.78
6 month return +172.11
1 year return +387.16
3 year return -63.35
5 year return -63.24
10 year return -

Institutional Holdings

Octagon Capital Advisors LP 8.07

NEA Management Company, LLC 7.96

BlackRock Inc 5.34

Vanguard Group Inc 5.02

ARCH VENTURE CORP 3.54

FMR Inc 3.22

Vanguard Total Stock Mkt Idx Inv 2.99

683 Capital Management LLC 2.79

Samsara BioCapital, LLC 2.70

Palo Alto Investors, LLC 2.52

Fidelity Select Biotechnology 2.40

Siren, L.L.C. 2.29

SILVERARC CAPITAL MANAGEMENT, LLC 2.26

Hillhouse Capital Advisors, Ltd. 2.19

iShares Russell 2000 ETF 2.04

Geode Capital Management, LLC 2.00

Alyeska Investment Group, L.P. 1.96

CI Private Wealth LLC 1.62

Monaco Asset Management 1.56

Opaleye Management Inc 1.56

Rock Springs Capital Management LP 1.44

Renaissance Technologies Corp 1.20

State Street Corp 1.09

Vanguard Institutional Extnd Mkt Idx Tr 0.90

Fidelity Small Cap Index 0.83

iShares Russell 2000 Growth ETF 0.74

Fidelity Extended Market Index 0.45

Schwab US Small-Cap ETF™ 0.41

Vanguard Russell 2000 ETF 0.40

Federated Hermes Kaufmann Small Cap A 0.34

Federated Hermes Kaufmann Small Cap Grow 0.34

State St Russell Sm Cap® Indx SL Cl I 0.29

Schwab Small Cap Index 0.21

Bridgeway Ultra-Small Company Market 0.20

NT R2000 Index Fund - NL 0.20

iShares Micro-Cap ETF 0.19

Extended Equity Market Fund K 0.18

Xtrackers S&P 500 Swap ETF 1C 0.18

NT R2000 Index Fund - DC - NL - 3 0.16

Fidelity Total Market Index 0.16

Market Status

Strong Buy: 4

Buy: 3

Hold: 2

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 692.05 M

PB Ratio 2.6638

PE Ratio 0.0

Enterprise Value 749.42 M

Total Assets 315.29 M

Volume 4711546

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-187433000 -187.4M, FY22:-240228000 -240.2M, FY21:-249076000 -249.1M, FY20:-251584000 -251.6M, FY19:-180818000 -180.8M

Quarterly Revenue Q3/2025:13294000 13.3M, Q2/2025:11489000 11.5M, Q1/2025:9889000 9.9M, Q3/2024:9480000 9.5M, Q2/2024:95842000 95.8M

Quarterly Profit Q3/2025:13294000 13.3M, Q2/2025:11489000 11.5M, Q1/2025:9889000 9.9M, Q3/2024:9480000 9.5M, Q2/2024:94850000 94.9M

Quarterly Net worth Q3/2025:-48221000 -48.2M, Q2/2025:-38273000 -38.3M, Q1/2025:-36638000 -36.6M, Q3/2024:-30803000 -30.8M, Q2/2024:49232000 49.2M

Fund house & investment objective

Company Information Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

Organisation Biotechnology

Employees 144

Industry Biotechnology

CEO Mr. Faheem Hasnain

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow